Cannabis Use Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Cannabis Use Disorder Market Outlook

Thelansis’s “Cannabis Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cannabis Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cannabis Use Disorder Overview

Cannabis as a Schedule I drug is classified by the FDA. The usage of cannabis exhibits variations across different demographic groups. Tetrahydrocannabinol (THC) serves as the primary compound responsible for the reinforcing effects of marijuana. Although the striatal dopamine system typically plays a role in substances of abuse, such as alcohol and opioids, current meta-analyses lack sufficient evidence to support a similar conclusion regarding cannabis. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) has updated the criteria for cannabis use disorder, delineating nine pathological patterns categorized under impaired control, social impairment, risky behavior, or physiological adaptation. It is focused on cannabis misuse and its associated elements, including states of intoxication, withdrawal, and cannabis use disorder. Moreover, dopamine receptors may not be directly involved. The primary objective is to enhance the overall functioning of the individual, which is a complex, multifaceted process. As cannabis strains become increasingly potent and accessible, there is a heightened risk of experiencing more frequent and severe adverse reactions. Treatment targeting specific symptoms may include the use of alpha-2-adrenergic agonists or beta-blockers to address tachycardia, benzodiazepines to manage panic attacks, off-label administration of first-generation antihistamines for alleviating anxiety and restlessness, and neuroleptics for addressing psychosis. Currently, no medication is approved by the FDA specifically for treating cannabis use disorder.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Cannabis Use Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment